[ad_1]
Germany’s Merck Life Sciences will set up an Asia-Pacific production facility for biopharmaceutical raw materials and parts in Daejeon, Korea.
Merck Life Sciences announced on May 3 that it has signed a memorandum of understanding (MOU) with the Ministry of Trade, Industry and Energy and Daejeon Metropolitan City to establish a production facility for raw materials used in biotech processes in the Asia-Pacific region in Daejeon.
The biopharmaceutical raw materials and parts include everything from protein enzymes used as raw materials for pharmaceuticals to vials that contain pharmaceutical liquids. The Daejeon plant will produce raw materials for pharmaceutical and biotech customers in the Asia-Pacific region. Merck will also support biotech venture companies in Daedeok Research Park in Daejeon and expand research collaborations with Korean colleges and universities in the biotech field.
“Under this agreement, we will actively support our customers in the Asia-Pacific region in close cooperation with the Korean government,” said Dr. Matthias Heinzel, CEO of Merck. “The Daejeon plant will serve as a hub for the development of the Korean pharmaceutical biotech industry while meeting the needs of the Asia-Pacific region.”
[ad_2]
Source link